This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Franzmann, E. J. Articles by Goodwin, W. J. Search for Related Content PubMed PubMed Citation Articles by Franzmann, E. J. Articles by Goodwin, W. J.

Soluble CD44 Is a Potential Marker for the Early Detection of Head and Neck Cancer

¹ University of Miami/Sylvester Comprehensive Cancer Center; ² Department of Otolaryngology; ³ Department of Cell Biology and Anatomy; ⁴ Division of Biostatistics, University of Miami/Sylvester Comprehensive Cancer Center; ⁵ Division of Medical Oncology, Department of Internal Medicine, University of Miami, Miami, Florida; and ⁶ NIH/National Institute on Deafness and Other Communication Disorders, Bethesda, Maryland

Requests for reprints: Elizabeth J. Franzmann, Jackson Medical Tower, East Room 1028, 1500 Northwest 12th Avenue, Miami, FL 33136. Fax: 305-243-3383. E-mail: efranzman{at}med.miami.edu

Introduction: Head and neck squamous cell carcinoma (HNSCC) is a devastating and deadly disease, largely because it is diagnosed in late stage. Cure rates, currently at 50%, could increase to >80% with early detection. In this study, we evaluate soluble CD44 (solCD44) as an early detection tool for HNSCC by determining whether it reliably distinguishes HNSCC from benign disease of the upper aerodigestive tract.

Methods: We carried out the solCD44 ELISA on oral rinses from 102 patients with HNSCC and 69 control patients with benign diseases of upper aerodigestive tract to determine the sensitivity and specificity of the test for differentiating HNSCC from benign disease. Furthermore, we did a pilot study using methylation-specific PCR primers on oral rinses from 11 HNSCC patients with low solCD44 levels and 10 benign disease controls.

Results: Mean salivary solCD44 levels were 24.4 ± 32.0 ng/mL for HNSCC patients (range, 0.99-201 ng/mL) and 9.9 ± 16.1 ng/mL (range, 0.73-124 ng/mL) for the patients with benign disease (P < 0.0001). Depending on cutoff point and HNSCC site, sensitivity ranged from 62% to 70% and specificity ranged from 75% to 88%. Nine of 11 HNSCC and 0 of 10 controls with low solCD44 levels showed hypermethylation of the CD44 promoter.

Conclusions: SolCD44 is elevated in the majority of HNSCC and distinguishes cancer from benign disease with high specificity. Whereas the solCD44 test lacks sensitivity by itself, methylation status of the CD44 gene seems to complement the solCD44 test. Our pilot data indicate that, together, these markers will detect HNSCC with very high sensitivity and specificity. (Cancer Epidemiol Biomarkers Prev 2007;16(7):1348–55)